BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 32888940)

  • 1. An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer.
    Li M; Li W; Yang X; Wang H; Peng Y; Yin J; Lu Y; Liu L; Shang J; Zhao Q
    Life Sci; 2020 Nov; 261():118368. PubMed ID: 32888940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of an immune prognostic signature in colorectal cancer.
    Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
    Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Landscape of Invasive Ductal Carcinoma Tumor Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature.
    Bao X; Shi R; Zhang K; Xin S; Li X; Zhao Y; Wang Y
    Front Oncol; 2019; 9():903. PubMed ID: 31620363
    [No Abstract]   [Full Text] [Related]  

  • 4. Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer.
    Hou Y; Zhang R; Zong J; Wang W; Zhou M; Yan Z; Li T; Gan W; Lv S; Zeng Z; Yang M
    Front Immunol; 2022; 13():892512. PubMed ID: 35711437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients.
    Zhu W; Wu C; Hu S; Liu S; Zhao S; Zhang D; Qiu G; Cheng X; Huang J
    Sci Rep; 2023 Dec; 13(1):21358. PubMed ID: 38049474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
    Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
    Front Immunol; 2022; 13():944286. PubMed ID: 36591255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
    Jiang W; Zhu D; Wang C; Zhu Y
    Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokine‑ and chemokine receptor-based subtypes predict prognosis, immunotherapy and chemotherapy response in colorectal cancer patients.
    Zhu W; Zhao S; Cheng X; Wu C; Liu Z; Huang J
    Int Immunopharmacol; 2024 Jun; 134():112172. PubMed ID: 38703566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
    Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
    Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.
    Zhang F; Zhang R; Zong J; Hou Y; Zhou M; Yan Z; Li T; Gan W; Lv S; Yang L; Zeng Z; Zhao W; Yang M
    Front Immunol; 2023; 14():1279789. PubMed ID: 37928532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel anoikis-related gene prognostic signature and its correlation with the immune microenvironment in colorectal cancer.
    Xiao Y; Zhou H; Chen Y; Liu L; Wu Q; Li H; Lin P; Li J; Wu J; Tang L
    Front Genet; 2023; 14():1186862. PubMed ID: 37323657
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor microenvironment characterization in colorectal cancer to identify prognostic and immunotherapy genes signature.
    Guo XW; Lei RE; Zhou QN; Zhang G; Hu BL; Liang YX
    BMC Cancer; 2023 Aug; 23(1):773. PubMed ID: 37596528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAF signature predicts the prognosis of colorectal cancer patients: A retrospective study based on bulk RNA sequencing and single-cell RNA sequencing data.
    Liang C; Ji D; Qin F; Chen G
    Medicine (Baltimore); 2023 Mar; 102(10):e33149. PubMed ID: 36897717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel prognostic immunoscore based on The Cancer Genome Atlas to predict overall survival in colorectal cancer patients.
    Tang Z; Wu Y; Sun D; Xue X; Qin L
    Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34608935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
    Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
    Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an anoikis-related gene signature and prognostic model for predicting the tumor microenvironment and response to immunotherapy in colorectal cancer.
    Li C; Weng J; Yang L; Gong H; Liu Z
    Front Immunol; 2024; 15():1378305. PubMed ID: 38779664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Talk Between m
    Song W; Ren J; Xiang R; Yuan W; Fu T
    Front Immunol; 2022; 13():740960. PubMed ID: 35350786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel Immune-Related prognostic model for patients with colorectal cancer based on 3 subtypes.
    Yang X; Wei Q
    Immunobiology; 2023 Mar; 228(2):152352. PubMed ID: 36827833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel identified pyroptosis-related prognostic signature of colorectal cancer.
    Zheng C; Tan Z
    Math Biosci Eng; 2021 Oct; 18(6):8783-8796. PubMed ID: 34814322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A robust immune-related lncRNA signature for the prognosis of human colorectal cancer.
    Zhu G; Pei L; Yang F; Zhang C
    Biosci Rep; 2022 Jul; 42(7):. PubMed ID: 35506372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.